Kidney Disease in the Setting of HIV Infection: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2018 Feb 6

PMID 29398134

Citations 84

Authors

Charles R Swanepoel

Mohamed G Atta

Vivette D DAgati

Michelle M Estrella

Agnes B Fogo

Saraladevi Naicker

Frank A Post

Nicola Wearne

Cheryl A Winkler

Michael Cheung

David C Wheeler

Wolfgang C Winkelmayer

Christina M Wyatt

Affiliations

Soon will be listed here.

Abstract

HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

Citing Articles

Risk of Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.

Wang J, Huang K, Tai C, Gau S, Tsai T, Wu C In Vivo. 2025; 39(2):1054-1066.

PMID: 40010982 PMC: 11884483. DOI: 10.21873/invivo.13910.

HIV and CKD in the Tenofovir Era: A Prospective Parallel-Group Cohort Study From Tanzania.

Roberts N, Fadhil S, Willkens M, Ruselu G, Desderius B, Kanenda S Kidney Med. 2025; 7(1):100937.

PMID: 39790232 PMC: 11714399. DOI: 10.1016/j.xkme.2024.100937.

The High Burden of Asymptomatic Kidney Diseases in Individuals with HIV: A Prospective Study from a Tertiary Care Center in India.

Giri K, Sahay M, Ismail K, Kavadi A, Rama E, Gowrishankar S Indian J Nephrol. 2024; 34(6):623-629.

PMID: 39649319 PMC: 11619057. DOI: 10.25259/ijn_10_24.

Comparison of the prevalence and associated factors of chronic kidney disease diagnosed by serum creatinine or cystatin C among young people living with HIV in Uganda.

Nasuuna E, Tomlinson L, Kalyesubula R, Dziva Chikwari C, Castelnuovo B, Manabe Y BMC Nephrol. 2024; 25(1):422.

PMID: 39587464 PMC: 11590532. DOI: 10.1186/s12882-024-03865-8.

Characterization of immortalized human podocytes infected with lentivirus as an model of viral infection-associated podocytopathy.

Yu P, Jin X, Huang W, Wang J, Zhang S, Ren L Am J Clin Exp Immunol. 2024; 13(5):204-214.

PMID: 39583339 PMC: 11578807. DOI: 10.62347/BBCX1142.

References

Boyarsky B, Segev D . From Bench to Bill: How a Transplant Nuance Became 1 of Only 57 Laws Passed in 2013. Ann Surg. 2015; 263(3):430-3. DOI: 10.1097/SLA.0000000000001352. View

Cohen A, Nast C . HIV-associated nephropathy. A unique combined glomerular, tubular, and interstitial lesion. Mod Pathol. 1988; 1(2):87-97. View

Inker L, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M . Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012; 61(3):302-9. PMC: 3598619. DOI: 10.1097/QAI.0b013e31826a6c4f. View

DAgati V, Suh J, Carbone L, Cheng J, APPEL G . Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989; 35(6):1358-70. DOI: 10.1038/ki.1989.135. View

Beckerman P, Bi-Karchin J, Park A, Qiu C, Dummer P, Soomro I . Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med. 2017; 23(4):429-438. PMC: 5603285. DOI: 10.1038/nm.4287. View

Locke J, Mehta S, Sawinski D, Gustafson S, Shelton B, Reed R . Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. Clin J Am Soc Nephrol. 2017; 12(3):467-475. PMC: 5338712. DOI: 10.2215/CJN.07460716. View

Atta M, Estrella M, Kuperman M, Foy M, Fine D, Racusen L . HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int. 2012; 82(3):338-43. PMC: 3463138. DOI: 10.1038/ki.2012.111. View

Karuthu S, Blumberg E . Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012; 7(12):2058-70. DOI: 10.2215/CJN.04410512. View

Muller E, Kahn D, Mendelson M . Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010; 362(24):2336-7. PMC: 5094174. DOI: 10.1056/NEJMc0900837. View

10.

Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan D, Lins L, Van Den Abbeele J . Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003; 422(6927):83-7. DOI: 10.1038/nature01461. View

11.

Shlipak M, Matsushita K, Arnlov J, Inker L, Katz R, Polkinghorne K . Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013; 369(10):932-43. PMC: 3993094. DOI: 10.1056/NEJMoa1214234. View

12.

Estrella M, Li M, Tin A, Abraham A, Shlipak M, Penugonda S . The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis. 2014; 60(4):646-52. PMC: 4318914. DOI: 10.1093/cid/ciu765. View

13.

Wreghitt T . Blood-borne virus infections in dialysis units--a review. Rev Med Virol. 1999; 9(2):101-9. DOI: 10.1002/(sici)1099-1654(199904/06)9:2<101::aid-rmv234>3.0.co;2-u. View

14.

Muller E, Barday Z, Mendelson M, Kahn D . HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med. 2015; 372(7):613-20. PMC: 5090019. DOI: 10.1056/NEJMoa1408896. View

15.

Farzadegan H, Ford D, Malan M, Masters B, Scheel Jr P . HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int. 1996; 50(5):1659-62. DOI: 10.1038/ki.1996.482. View

16.

Kopp J, Nelson G, Sampath K, Johnson R, Genovese G, An P . APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011; 22(11):2129-37. PMC: 3231787. DOI: 10.1681/ASN.2011040388. View

17.

Estrella M, Wyatt C, Pearce C, Li M, Shlipak M, Aouizerat B . Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013; 84(4):834-40. PMC: 3788838. DOI: 10.1038/ki.2013.203. View

18.

Bruggeman L, Wu Z, Luo L, Madhavan S, Konieczkowski M, Drawz P . APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease. J Am Soc Nephrol. 2016; 27(12):3600-3610. PMC: 5118487. DOI: 10.1681/ASN.2015111220. View

19.

Kimmel P, Phillips T, Abraham A, Garrett C . HIV-associated immune-mediated renal disease. Kidney Int. 1993; 44(6):1327-40. DOI: 10.1038/ki.1993.386. View

20.

Perez-Molina J, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M . Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority.... Lancet Infect Dis. 2015; 15(7):775-84. DOI: 10.1016/S1473-3099(15)00097-3. View